Therapeutic drug monitoring of mirtazapine and its metabolite desmethylmirtazapine by HPLC with fluorescence detection

Therapeutic Drug Monitoring

Volumn 26, Issue 3, 2004, Pages 277-283

  Meineke, Ingolf ^a   Kress, Iris ^a   Poser, Wolfgang ^a   Rüther, Eckart ^a   Brockmöller, Jürgen ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Concentration effect relationship; HPLC; Mirtazapine

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DRUG METABOLITE; MIRTAZAPINE; NORMIRTAZAPINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CALIBRATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; EXTRACTION; FEMALE; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; QUALITY CONTROL;

ADRENERGIC ALPHA-ANTAGONISTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; MALE; MIANSERIN; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, FLUORESCENCE;

EID: 2542603002     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200406000-00010     Document Type: Article

References (12)

1. Voortman G, Paanakker JE. Bioavailability of mirtazapine from Remeron tablets after single and multiple oral dosing. Hum Psychopharmacol. 1995;10:S83-S96.
2. Delbressine LPC, Moonen MEG, Kaspersen FM, et al. Pharmacokinetics and biotransformation of mirtazapine in human volunteers. Clin Drug Invest. 1998;15:45-55.
3. Paanakker JE, van Hal HJM. Capillary gas chromatographic assay for the routine monitoring of the antidepressant mepirzepine in human plasma. J Chromatogr. 1987;417:203-207.
4. Maris FA, Dingler E, Niehues S. High-performance liquid chromatographic assay with fluorescence detection for the routine monitoring of the antidepressant mirtazapine and its demethylmetabolite in human plasma. J Chromatogr. 1999;721:309-316.
5. Romiguieres T, Pehourq F, Matoga M, et al. Determination of mirtazapine and its demethylmetabolite in plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr. 2002;775:163-168.
6. Timmer CJ, Paanakker JE, van Hal HJM. Pharmacokinetics of mirtazapine from orally administered tablets: Influence of gender, age and treatment regime. Hum Psychopharmacol. 1996;11:497-509.
7. Cohen M, Panagides J, Timmer CJ, et al. Pharmacokinetics of mirtazapine from orally administered tablets: influence of a high-fat meal. Eur J Drug Metab Pharmacokinet. 1997;22:103-110.
8. Sitsen JMA, Zivkov M. Mirtazapine clinical profile. CNS Drugs. 1995;4:38-48.
9. Dodd S, Burrows GD, Norman TR. Chiral determination of mirtazapine in human blood plasma by high-performance liquid chromatography. J Chromatogr. 2000;748:439-443.
10. Ptacek P, Klima J, Macek J. Determination of mirtazapine in human plasma by liquid chromatography. J Chromatogr. 2003;794:323-328.
11. Morgan PE, Tapper J, Spencer EP. Measurement of total mirtazapine and normirtazapine in plasma/serum by liquid chromatography with fluorescence detection. J Chromatogr. 2003;798:211-215.
12. Meyer-Barner M, Meineke I, Schreeb KH, et al. Pharmacokinetics of doxepin and desmethyldoxepin: an evaluation with the population approach. Eur J Clin Pharmacol. 2002;58:253-257.